Navigation Links
Derma Sciences To Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference
Date:9/2/2009

PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, will present at Rodman & Renshaw's Eleventh Annual Healthcare Conference taking place September 9 - 11, 2009, at the New York Palace Hotel. Edward J. Quilty, Chairman and Chief Executive Officer will give the company presentation on Friday, September 11, 2009, 9:10AM EDT in the Fahnestock Salon (fifth floor). Additional information regarding the conference can be found at http://rodm.com/conferences?id=30.

Expected to welcome 3,500 guests and include presentations by over five hundred companies, the Conference will be attended by investors, venture capitalists, company executives, medical experts, scientists, and other industry leaders. To access a live audio webcast or the subsequent archived recording, log on to http://www.wsw.com/webcast/rrshq15/dsci.ob. Please connect to the website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.

For more news and information on Derma Sciences, Inc., please visit www.IRGnews.com/coi/DSCI where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.

    Contact:

        Derma Sciences, Inc.
        Edward J. Quilty
        Chairman and CEO
        equilty@dermasciences.com
        (609) 514- 4744

        Contact:

        The Investor Relations Group
        212-825-3210
        Investor Relations:
        Rachel Olson
        or
        Michael Crawford
        Or
        Media Relations:
        Susan Morgenbesser


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dermal Filler Procedures Jump 30% at Center For Cosmetic and Plastic Surgery
2. Painless, Bruise-free Dermal Filler Injections
3. IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests
4. Solve Skin Conditions and Receive Hair Loss Treatment from Home with New Line of Medical Devices Called Dermaray
5. Portland Dermatologists to Show LPGA Safeway Classic Fans How to Play Safe in the Sun
6. Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
7. CSC Announces Agreement to Provide Billing Service to Colorado West Dermatology
8. Derma Sciences Reports Second Quarter 2009 Results
9. Illinois Dermatologists Tee Up for Sun Safety at Two World-Class Golf Championships
10. Rodan + Fields Dermatologists Launch National Hispanic Outreach Campaign
11. Making The Outdoors Safer for Communities: The American Academy of Dermatology Announces 2009 AAD Shade Structure Program Grant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: